These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 24304669

  • 1. The role of risedronate in osteopenia in Crohn's disease.
    Buchan A, Manuel A.
    Gut; 2015 Jan; 64(1):185. PubMed ID: 24304669
    [No Abstract] [Full Text] [Related]

  • 2. Authors' response: The role of risedronate in osteopenia in Crohn's disease.
    van Bodegraven AA, Witte BI, Lips P, Crohn and Bone Study Group of the Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2015 Jan; 64(1):185-6. PubMed ID: 24569060
    [No Abstract] [Full Text] [Related]

  • 3. What is the role for bisphosphonates in IBD?
    Bernstein CN, Targownik LE, Leslie WD.
    Gut; 2014 Sep; 63(9):1369-70. PubMed ID: 24221457
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [Abstract] [Full Text] [Related]

  • 5. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I, Siffledeen J, Siminoski K, McQueen B, Fedorak RN.
    J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
    [Abstract] [Full Text] [Related]

  • 6. Risedronate improves bone mineral density in Crohn's disease: a complementary mechanism.
    Namazi H.
    J Crohns Colitis; 2012 Jul; 6(6):734. PubMed ID: 22483568
    [No Abstract] [Full Text] [Related]

  • 7. Clinical Course of Bone Metabolism Disorders in Patients with Inflammatory Bowel Disease: A 5-Year Prospective Study.
    Casals-Seoane F, Chaparro M, Maté J, Gisbert JP.
    Inflamm Bowel Dis; 2016 Aug; 22(8):1929-36. PubMed ID: 27135482
    [Abstract] [Full Text] [Related]

  • 8. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
    Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G.
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):122-32. PubMed ID: 15704046
    [Abstract] [Full Text] [Related]

  • 9. Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation.
    Bakker SF, Dik VK, Witte BI, Lips P, Roos JC, Van Bodegraven AA.
    J Crohns Colitis; 2013 Jun; 7(5):377-84. PubMed ID: 22749232
    [Abstract] [Full Text] [Related]

  • 10. [Antiresorptive treatment after proximal femur fracture].
    Muñoz VL, Roger DR, Valle MB, García LL.
    Aten Primaria; 2005 Nov; 36(8):467. PubMed ID: 16287563
    [Abstract] [Full Text] [Related]

  • 11. [Osteoporosis management in general practice. Preventing spontaneous bone fractures].
    MMW Fortschr Med; 2010 Jul 01; 152(25-27):54-5. PubMed ID: 20672666
    [No Abstract] [Full Text] [Related]

  • 12. Is the increase in osteoporosis prevention a result of the audit?
    Naunton M.
    Clin Neurol Neurosurg; 2006 Oct 01; 108(7):718-9. PubMed ID: 16621242
    [No Abstract] [Full Text] [Related]

  • 13. Weekly risedronate in kidney transplant patients with osteopenia.
    Torregrosa JV, Fuster D, Pedroso S, Diekmann F, Campistol JM, Rubí S, Oppenheimer F.
    Transpl Int; 2007 Aug 01; 20(8):708-11. PubMed ID: 17555530
    [Abstract] [Full Text] [Related]

  • 14. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K.
    J Bone Miner Res; 2006 Oct 01; 21(10):1581-90. PubMed ID: 16995813
    [Abstract] [Full Text] [Related]

  • 15. Fracture prevention in postmenopausal women.
    Mosekilde L, Vestergaard P, Langdahl B.
    Clin Evid; 2006 Jun 01; (15):1543-60. PubMed ID: 16973058
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
    Ringe JD, Faber H, Farahmand P, Dorst A.
    Rheumatol Int; 2006 Mar 01; 26(5):427-31. PubMed ID: 16001181
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
    Yurci A, Kalkan AO, Ozbakir O, Karaman A, Torun E, Kula M, Baskol M, Gursoy S, Yucesoy M, Bayram F.
    Eur J Gastroenterol Hepatol; 2011 Nov 01; 23(12):1206-12. PubMed ID: 21971374
    [Abstract] [Full Text] [Related]

  • 18. Osteoporosis in older people: a tale of two studies (and three treatments).
    Troen BR.
    J Am Geriatr Soc; 2006 May 01; 54(5):853-5. PubMed ID: 16696755
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT.
    Vanlint SJ, Ried K.
    Maturitas; 2012 Jan 01; 71(1):44-8. PubMed ID: 22078660
    [Abstract] [Full Text] [Related]

  • 20. Review of treatment modalities for postmenopausal osteoporosis.
    Hamdy RC, Chesnut CH, Gass ML, Holick MF, Leib ES, Lewiecki ME, Maricic M, Watts NB.
    South Med J; 2005 Oct 01; 98(10):1000-14; quiz 1015-7, 1048. PubMed ID: 16295815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.